http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0585705-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7ad58d3c0b071069a8ee0cb8c8ba2e8
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
filingDate 1993-08-16^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 1998-11-04^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_082f68eb6a9c0692af09cb7fe5135de5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_928492145ce1bec629c90b2a095eb267
publicationDate 1998-11-04^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0585705-B1
titleOfInvention Use of monoclonal antibodies to TNF to treat bacterial meningitis
abstract Bacterial meningitis infection in a mammal is treated by intravenous infusion of therapeutically effective amounts of monoclonal antibodies which bind to tumor necrosis factor alpha. Treatment can be initiated up to five hours after bacterial challenge and is preferably in combination with an antibiotic selected from cephalosporins and aminoglycosides.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9295725-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9061005-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8795670-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9302011-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9114166-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8961974-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7820169-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8916157-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8916158-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9499615-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9327032-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9289497-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7815909-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8961973-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8940305-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9272041-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9272042-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8932591-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11124565-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8802100-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8911741-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8802101-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8802102-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9220781-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9187559-B2
priorityDate 1992-08-28^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5479530
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1977
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403922
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395375
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID7124
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412101
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226419997
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57134040
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412100
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID21926
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1359
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1017
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID120
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9816401
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5361919
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID51800
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129445248

Showing number of triples: 1 to 59 of 59.